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Abstract
Background: Type 2 diabetes mellitus (T2DM) is commonly associated with both microvascular
and macrovascular complications and a strong correlation exists between glycaemic control and
the incidence and progression of vascular complications. Pioglitazone, a Peroxisome proliferator-
activated receptor-γ (PPARγ) ligand indicated for therapy of type T2DM, induces vascular effects
that seem to occur independently of glucose lowering.
Methods: By using a hindlimb ischemia murine model, in this study we have found that pioglitazone
restores the blood flow recovery and capillary density in ischemic muscle of diabetic mice and that
this process is associated with increased expression of Vascular Endothelial Growth Factor (VEGF).
Importantly, these beneficial effects are abrogated when endogenous Akt is inhibited; furthermore,
the direct activation of PPARγ, with its selective agonist GW1929, does not restore blood flow
recovery and capillary density. Finally, an important collateral vessel growth is obtained with
combined treatment with pioglitazone and selective PPARγ inhibitor GW9662.
Conclusion: These data demonstrate that Akt-VEGF pathway is essential for ischemia-induced
angiogenic effect of pioglitazone and that pioglitazone exerts this effect via a PPARγ independent
manner.
Background
Diabetes mellitus is commonly associated with both
microvascular and macrovascular complications such as
coronary artery disease, cerebrovascular events, severe
peripheral vascular disease, nephropathy and retinopathy
[1]. Vascular function in diabetes has been studied exten-
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sively in both animal models and humans [2-4], and
impaired endothelium-dependent vasodilatation has
been documented as a consistent finding in animal mod-
els of diabetes induced by alloxan or streptozotocin [5,6].
Consistently, in vivo studies have confirmed that hypergly-
cemia directly induces endothelial dysfunction both in
diabetic and healthy subjects [7]. Moreover an experimen-
tal animal model has shown a decreased ability of diabetic
mice in restoring the blood flow and the capillarity den-
sity after hind-limb ischemia [8]. Thiazolidinedione
derivatives (TZDs), such as pioglitazone, troglitazone and
rosiglitazone, are indicated for therapy of type 2 diabetes
mellitus (T2DM). They have been demonstrated to be
effective alone or in combination with a sulfonylurea,
metformin, or insulin. Pioglitazone is an insulin sensitizer
that promotes glucose metabolism without increasing
insulin secretion [9]. In addition to its insulin sensitizing
effects, increasing evidence suggests that this drug
improve vascular health, vascular function and inflamma-
tory biomarkers of arteriosclerosis [10-12]. Interestingly,
these vascular effects seem to occur independently of glu-
cose lowering and have been demonstrated also in non-
diabetic, healthy individuals [10,12-14]. These findings
have led to the hypothesis that pioglitazone could exert
vasculoprotective effects that are independent of its meta-
bolic action.
Peroxisome proliferator-activated receptors (PPARs) are
the major ligands of TZDs and Peroxisome proliferator-
activated receptor-γ (PPARγ) is the receptor mediating
TZDs' antidiabetic effects [15]. TZDs are non-selective and
non-specific ligands of PPARs and they are able to stimu-
late several PPARγ-independent pathways [16-21]. There-
fore, the vasculoprotective effect of pioglitazone could be
unrelated to the activation of PPARγ.
Akt is a central signaling molecule in regulating cell sur-
vival, proliferation, tumor growth and angiogenesis [22].
Short-term Akt activation in inducible Akt1 transgenic
mice induces physiological cardiac hypertrophy with
maintained vascular density [23], indicating that coronary
angiogenesis is enhanced to keep pace with the growth of
the myocardium. Similar observations have also been
made in skeletal muscle cells: Akt activation results in
myofiber growth associated with enhanced Vascular
Endothelial Growth Factor (VEGF), a prototypical ang-
iogenic agent, secretion and induces blood vessel recruit-
ment [24]. VEGF and Angiopoietin-2 (Ang-2) are key
angiogenic growth factors induced by hypoxia [25], and
expression of these two growth factors is enhanced by
short-term Akt activation in the myocardium [23]. Fur-
thermore, transgenic co-expression of VEGF and Ang-2
exhibits synergistic effects on induction of coronary ang-
iogenesis in the myocardium [26]. Thus, Akt-mediated
growth-promoting signals act to enhance angiogenesis in
a paracrine manner, providing a mechanism by which
angiogenesis is coordinately regulated. Some authors
have shown that the treatment with pioglitazone in an
experimental model of hind-limb ischemia in diabetic
mice up-regulates VEGF expression and this is associated
with the phosphorylation/activation of eNOS at Ser1177
and Akt at Ser473 [8]. Given pre-existing data, we hypothe-
sized that pioglitazone could improve impaired angiogen-
esis in diabetic mice by Akt-VEGF pathway, independently
of PPARγ receptor.
Methods
Animals and drugs administration
The investigation was approved by A. Gemelli University
Hospital Institutional Animal Care and Use Committee.
Male 8-12-week-old C57BL/6J mice were used for experi-
ments. Diabetes was induced by administering 50 mg/kg
body wt streptozotocin (STZ; Sigma) in citrate buffer (pH
4.5), intraperitoneally (i.p.) during the fasting state, for 5
days, as previously described [27]. Hyperglycemia was
verified 2 days after STZ injection by an Accu-Check Active
glucometer (Roche). We considered mice to be diabetic
when blood glucose was at least 16 mmol/l (normal 5-8
mmol/l). Overall, 50 mice showed a blood glucose level
of at least16 mmol/l, both 1 and 2 week after the STZ
injection and, therefore, were included in the experimen-
tal diabetic group. A first group of 10 STZ-diabetic mice
received pioglitazone (3 mg/kg per day) by gavage for two
weeks [8]. To evaluate whether the effect of pioglitazone
was mediated by PPARγ, a second group of 10 STZ-dia-
betic pioglitazone-treated mice, received a PPARγ selective
antagonist, GW9662 (Sigma), at the dosage of 2 mg/kg
i.p., administered 1 h before pioglitazone [28]. To evalu-
ate whether the effect of pioglitazone was mediated by
Akt, a third group of 10 STZ-diabetic pioglitazone-treated
mice, FPA-124 (Echelon), a cell-permeable inhibitor of
Akt (Sigma), was administered by gavage at the dosage of
20 mg/kg/bid, everyday of pioglitazone-treatment period
[29,30]. Finally, to evaluate the role of PPARγ on
ischemia-induced angiogenesis, a fourth group of 10 STZ-
diabetic mice was gavaged twice daily for two weeks with
GW1929 (Sigma), a PPARγ selective agonist, at 5 mg/kg
dosage [31]. The last group of 10 STZ-diabetic mice
received vehicle (0.5% carboxymethyl cellulose) by gav-
age everyday for two weeks after surgery. Finally, 10
untreated C57BL/6J mice were also included in the
model. The last two groups were used as controls.
Mouse hindlimb ischemia model
After two weeks from the beginning of the treatment with
pioglitazone (n = 10), pioglitazone + GW9662 (n = 10),
pioglitazone + FPA-124 (n = 10), GW1929 (n = 10), uni-
lateral hindlimb ischemia was induced by excising the
right femoral artery, as previously described [32]. Right
femoral artery ligation was used to induce hindlimbCardiovascular Diabetology 2009, 8:49 http://www.cardiab.com/content/8/1/49
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ischemia in untreated and the STZ-diabetic mice receiving
vehicle. Briefly, all animals were anesthetized with an i.p.
injection of ketamine (60 mg/kg) and xylazine (8 mg/kg).
The proximal and distal portions of the femoral artery and
the distal portion of the saphenous artery were ligated.
The arteries and all side branches were dissected free and
excised. The skin was closed with 5-0 surgical suture. A
laser Doppler perfusion imager system (PeriScan PIM II,
Perimed) was used to measure hindlimb blood perfusion
before and after surgery and then followed at 7-day inter-
vals, until the end of the study, for a total follow-up of 28
days after surgery [32]. Before imaging, excess hairs were
removed from the limbs using depilatory cream and mice
were placed on a heating plate at 40°C. To avoid the influ-
ence of ambient light and temperature, results were
expressed as the ratio between perfusion in the right
(ischemic) versus left (non-ischemic) limb.
Histological Assays
At one and four weeks after surgery, mice were sacrificed
by i.p. injection of an overdose of pentobarbital. The
whole limbs were fixed in methanol overnight. The fem-
ora were carefully removed, and the ischemic thigh mus-
cles were embedded in paraffin. All the specimens were
routinely fixed overnight in 4% buffered formalin and
embedded in paraffin. The sections for immunohisto-
chemistry were collected on 3-aminopropyltriethoxy-
silane (Sigma), allowed to dry overnight at 37°C to ensure
optimal adhesion, dewaxed, rehydrated, and treated with
0.3% H2O2 in methanol for 10 min to block endogenous
peroxidase. For antigen retrieval (CD31 only, not neces-
sary for VEGF) the section were microwave treated in 1
mM EDTA at pH 8 for 10 min and allowed to cool for 20
min. Endogenous biotin was saturated using a biotin
blocking kit (Vector Laboratories). The sections were incu-
bated at room temperature for 30 min with the following
antibodies: purified rat anti-mouse CD31 [dilution 1:30;
monoclonal (IgG2a); BD Bioscience] and rabbit anti-
mouse VEGF [dilution 1:100, polyclonal, Santa Cruz Bio-
technology]. The slides were incubated for 1 h in the
humid chamber at room temperature, then with peroxi-
dase-conjugated secondary antibodies for 10 minutes,
washed, incubated with DAB and counterstained with
hematoxylin. Capillary density was measured by counting
six random high-power (magnification × 200) fields or a
minimum of 200 fibers from each ischemic and non-
ischemic limb on an inverted light microscope, and was
expressed by the number of CD31+ cells per square mil-
limeter or per fiber. Area was measured with a NIH Image
analysis system (ImageJ 1.41). Two operators extracted
independently the results.
Western Blotting
Immunoblotting was performed on homogenates of mus-
cle tissues. Proteins (40 mg per lane) were separated in
10% SDS-polyacrylamide gels and transferred onto poly-
vinylidine difluoride membranes [33]. Membranes were
incubated with antibodies against phospho-Akt (Ser473,
1:500, Cell Signaling Technology Company), Akt
(1:1000, New England Biolabs) and VEGF (1:500, R&D
Systems). Antibody binding was detected with horserad-
ish peroxidase-conjugated secondary antibodies (1:2000;
Chemicon) and enhanced chemiluminescence system
(GE Healthcare Bioscience). Finally, the blots were rep-
robed with total Akt, VEGF, or actin (1:5000, Sigma).
Statistics
All data are expressed as mean value ± SEM. Statistical
comparisons of means were performed by ANOVA fol-
lowed by Student's t-test. A p value of < 0.05 was consid-
ered to be statistically significant.
Results
Pioglitazone enhances blood flow recovery in diabetic 
mice after hind-limb ischemia
Pioglitazone treatment results in improved perfusion and
favorably modulation of capillary density in ischemic
skeletal muscle of diabetic mice. Laser Doppler perfusion
imaging was performed before, immediately after and on
days 7, 14, 21 and 28 after surgery. Perfusion recovery was
significantly attenuated in STZ-diabetic mice treated with
vehicle, compared with normoglycemic mice (Fig. 1a)
and, as previously reported [8], pioglitazone restored the
blood flow recovery in STZ-diabetic mice, reaching almost
80% of the blood flow of the untreated leg in four weeks
(Fig. 1a). Collateral vessel formation was also histologi-
cally evaluated by the capillary density of the ischemic
hindlimb muscle collected two and four weeks after sur-
gery (Fig. 2). Consistently with the measurement of laser
Doppler imaging, anti-CD31 immunostaining revealed
that angiogenesis in the ischemic hindlimb is impaired in
the diabetic mice treated with vehicle. Pioglitazone signif-
icantly restored the number of detectable capillaries in the
ischemic leg of the diabetic mice to a normal level (Fig. 2).
Pioglitazone-induced angiogenic response occurs in 
association with VEGF production and increases 
phosphorylation of Akt
Immunostaining revealed that VEGF expression had
increased in the ischemic tissue of normoglycemic mice
compared to STZ-diabetic mice (Fig. 3). VEGF concentra-
tion in ischemic tissue was also significantly higher in
pioglitazone-treated STZ-mice than in untreated STZ-dia-
betic mice (Fig. 3), underlying the crucial role of VEGF in
pioglitazone-induced angiogenic response. To further
investigate the mechanism by which pioglitazone stimu-
lates angiogenesis in diabetic mice, we evaluated VEGF
and Akt expression in the ischemic leg 7 days after surgery
by Western blotting analysis (Fig. 3). Pioglitazone nor-
malized VEGF expression and induced phosphorylation/Cardiovascular Diabetology 2009, 8:49 http://www.cardiab.com/content/8/1/49
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activation of Akt at Ser473, which expression was reduced
in diabetic mice treated with vehicle.
The ability of pioglitazone in normalizing the expression of 
VEGF, activating Akt and restoring blood flow is 
independent of PPAR  activation
To determine if pioglitazone-induced angiogenic
response in STZ-diabetic mice depends on activation of
PPARγ, we compared two groups of STZ-diabetic mice
undergoing hindlimb ischemia with selective PPARγ ago-
nist GW1929 (n = 10) or with pioglitazone associated
with selective PPARγ inhibitor GW9662 (n = 10). Laser
Doppler perfusion imaging was performed before, imme-
diately after and on days 7, 14, 21 and 28 after surgery.
Surprisingly, the treatment with GW1929 did not exert
any effect on ischemic muscle (Fig. 1b), on VEGF expres-
sion (Fig. 3) and on blood flow recovery, while pioglita-
zone maintained its activity in normalizing the expression
of VEGF (Fig. 3), activating Akt and restoring blood flow
also in mice where PPARγ was inhibited by GW9662 (Fig.
1a).
These results suggest that pioglitazone presides its favora-
ble effects on ischemic-induced angiogenesis regardless of
PPARγ activity.
The activity of pioglitazone on VEGF expression and blood 
flow recovery was abolished by selective inhibition of Akt
To confirm the hypothesis that the up-regulation of VEGF
induced by pioglitazone occurs through the activation of
Akt pathway, we inhibited Akt in diabetic mice subjected
to hind-limb ischemia and pre-treated with pioglitazone.
Seven days after surgery Akt was inhibited and pioglita-
zone had no effect on VEGF expression of ischemic mus-
cles in diabetic mice (Fig. 3). Furthermore, combined
treatment of pioglitazone with FPA-124, a selective Akt
inhibitor, had no effect on blood flow recovery evaluated
by laser Doppler (Fig. 1c).
Discussion
In this study, we have investigated the effect of pioglita-
zone on angiogenesis in response to tissue ischemia in
diabetic mice. We have been able to show that vascular
a. Foot blood flow monitored in vivo by laser Doppler perfusion imaging (LDPI) in control, STZ-diabetic, pioglitazone-treated  and pioglitazone+GW9662-treated mice Figure 1
a. Foot blood flow monitored in vivo by laser Doppler perfusion imaging (LDPI) in control, STZ-diabetic, piogl-
itazone-treated and pioglitazone+GW9662-treated mice. Evaluation of the ischemic (right) and non-ischemic (left) 
hindlimbs, immediately after and on days 7, 14, 21 and 28 after surgery. Red indicates normal perfusion while blue a marked 
reduction in blood flow of ischemic hindlimb. Pioglitazone restored blood flow recovery in diabetic mice, compared with nor-
moglycemic mice. Interestingly, pioglitazone associated with selective PPARγ inhibitor GW9662 restored blood flow recovery 
in diabetic mice. The blood flow of the ischemic hindlimb is expressed as the ratio between perfusion of the ischemic limb ver-
sus uninjured limb. *p < 0.05 vs control, STZ-diabetic and pioglitazone-treated mice. b. LDPI in control, STZ-diabetic, 
GW1929-treated mice. Selective PPARγ agonist GW1929 did not restore blood flow recovery in diabetic mice, compared with 
normoglycemic and STZ-diabetic mice.*p < 0.05 vs STZ-diabetic and GW1929-treated mice. c. LDPI in control, STZ-diabetic 
and pioglitazone+FP-124-treated mice. Pioglitazone associated with selective Akt inhibitor FP-124 did not restore blood flow 
recovery in diabetic mice, compared with normoglycemic and STZ-diabetic mice.*p < 0.05 vs STZ-diabetic and pioglita-
zone+FP-124-treated mice.Cardiovascular Diabetology 2009, 8:49 http://www.cardiab.com/content/8/1/49
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Akt system plays an important role in ischemia-induced
angiogenesis in pioglitazone-treated mice in vivo. In fact,
pioglitazone failed to promote blood flow recovery when
Akt activity was inhibited by FP-124, indicating that Akt is
an essential co-factor to promote collateral growth in
response to tissue ischemia during treatment with piogli-
tazone. To the best of our knowledge, this is the first study
demonstrating the important roles of vascular Akt system
in ameliorating endothelial dysfunction and restoring
ischemia-induced angiogenesis in diabetic mice treated
with pioglitazone, including induction of post-ischemic
angiogenesis and secretion of VEGF from ischemic mus-
cle. In addition, this study demonstrates that the positive
effect of pioglitazone occurs via a PPARγ independent
mechanism.
T2DM is a leading cause of morbidity and mortality that
places a substantial economic and health burden on the
public. Although the increased death rate is mainly due to
cardiovascular disease, deaths from non-cardiovascular
causes are also increasing [34]. T2DM is commonly asso-
ciated with both microvascular and macrovascular com-
plications [35]. A strong correlation exists between
glycaemic control and the incidence and progression of
microvascular complications [36], while its impact on
macrovascular events evolution seems weaker [37]. Sev-
eral long-term diabetes mellitus complications are charac-
terized by vasculopathy associated with aberrant
angiogenesis. Excessive angiogenesis plays an important
role in diabetic retinopathy, nephropathy and neuropathy
whereas inhibited angiogenesis contributes to impaired
wound healing and impaired coronary collateral vessel
development. Indeed, diabetic neuropathy is linked to
reduced nutritive blood flow secondary to diabetes and
could potentially be improved by inducing angiogenesis
in regions of inadequate perfusion [38]. Furthermore, the
increased glomerular filtration rate in diabetic nephropa-
thy may be the consequence of an enlarged glomerular fil-
tration surface resulting from excessive angiogenesis [39].
Moreover, diabetic patients frequently suffer of chronic
non-healing ulcers usually localized on pressure points of
the foot [40] and the presence of small abnormal blood
vessels has been reported at the wound edge of diabetic
ulcers [41]. The increased morbidity and mortality related
to atherosclerosis and the ensuing coronary and periph-
eral artery disease may be due to an impaired ability to
form collateral vessel in the diabetic scenario [42]. Indeed,
these patients often present a wide vascular disease and a
great number of vascular occlusions, due to diabetes-
induced deficiencies of angiogenesis [43]. Diabetes-
induced impairment of collateral formation has been also
demonstrated in murine models: hindlimb ischemia cre-
ated by ligation of the femoral artery is associated with a
reduced formation of capillaries and a reduction in blood
flow to the ischemic limb in diabetic versus non-diabetic
mice [44]. Thus, several agents are implicated in develop-
ment of abnormal angiogenesis in diabetes mellitus,
including dysregulation of VEGF local expression [45,46]
and other growth factors or cytokines imbalances [47,48]
in a general metabolic derangement [49].
PPARs are considered important factors for ameliorating
hyperlipidemia and hyperglycemia in subjects with
T2DM. PPARγ activation improves insulin sensitivity,
decreases inflammation, plasma levels of free fatty acids
and blood pressure, so indirectly leading to inhibition of
atherogenesis, improvement of endothelial function and
reduction of cardiovascular events. The insulin-sensitizing
drugs TZDs, as PPARγ agonists, have beneficial effects on
serum lipids in diabetic patients and have also been
shown to inhibit the progression of atherosclerosis in ani-
mal models [17]. Increasing evidence suggests that TZDs
improve endothelium-dependent vascular function and
inflammatory biomarkers of arteriosclerosis, independ-
ently of glucose-lowering effect in diabetic and non-dia-
betic individuals [50]. Interestingly, TZDs were reported
to increase VEGF expression in human vascular smooth
muscle cells [51], to promote angiogenesis after focal cer-
a. Representative photomicrographs of ischemic muscle sec- tions from pioglitazone+GW9662-treated and from pioglita- zone+FP-124-treated diabetic mice stained with antibody  directed against CD-31, 28 days after surgery Figure 2
a. Representative photomicrographs of ischemic 
muscle sections from pioglitazone+GW9662-treated 
and from pioglitazone+FP-124-treated diabetic mice 
stained with antibody directed against CD-31, 28 
days after surgery. Positive staining appears in brown. 
Magnification ×40. Number of vessels per cross section is sig-
nificantly reduced in pioglitazone+FP-124-treated diabetic 
mice respect to GW9662-treated diabetic mice. b. Quantifi-
cation of ischemia-induced angiogenesis 14 and 28 days after 
surgery. Number of vessels per cross section is significantly 
reduced in STZ-diabetic, pioglitazone+FP-124-treated and 
GW1929-treated mice vs STZ-diabetic, pioglitazone+FP-124-
treated and GW9662-treated mice (p < 0.01 at 14 days and p 
< 0.05 at 28 days).Cardiovascular Diabetology 2009, 8:49 http://www.cardiab.com/content/8/1/49
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ebral ischemia [52] and to reduce myocardial infarction
size in animal model [53]. Recent findings showed that
pioglitazone restores the impaired angiogenesis in
ischemic muscle of diabetic mice [8]. In all these studies,
Authors have assumed that the effects induced by TZDs
were mediated by the activation of PPARγ, without con-
sidering that TZDs are non-selective and non-specific lig-
ands of this nuclear receptor, since they are able to
stimulate several PPARγ-independent pathways that are
important in angiogenesis [18-21,54]. About pioglita-
zone, there are many biological effects idipendent of
PPARγ activation; in fact, pioglitazone causes PPARγ-inde-
pendent relaxation of isolated blood vessel [55], inhibits
homocysteine-induced vascular smooth muscle cells
migration that is independent of PPARγ [56] and prevents
apoptosis of endothelial progenitor cells (EPCs) in mice
as well as in human EPCs in a PI3K-dependent manner
[57]. Furthermore, this agent inhibits lung cancer cell
growth and its antiproliferative action does not occurs via
PPARγ activation [58]. Importantly, pioglitazone is
metabolized predominantly via the CYP 3A4, CYP 2C8
and CYP 1A1 pathways, through hydroxylation and oxi-
dation [59] and, since the CYP 3A4 metabolic pathway is
common to the metabolism of several drugs, the potential
for drug interactions and consequent alterations in effi-
cacy and safety of numerous concomitant medications
should be considered when this drug is co-administered
with CYP 3A4-metabolized agents. Effectively, pioglita-
zone stimulates PPARγ but the vasculoprotective effects
could be unrelated to the activation of PPARγ.
In a hindlimb ischemia murine model, our results con-
firm that diabetic mice display a decreased angiogenic
response, that pioglitazone restores the blood flow recov-
ery and capillary density in ischemic muscle and that this
process is associated with increased expression of VEGF.
Importantly, these beneficial effects are abrogated when
endogenous Akt is inhibited; furthermore, the direct acti-
vation of PPARγ, with its selective agonist GW1929, does
not restore blood flow recovery and capillary density.
Finally, an important collateral vessel growth is obtained
with combined treatment with pioglitazone and selective
PPARγ inhibitor GW9662. These data demonstrate that
Akt pathway is essential for ischemia-induced angiogenic
effect of pioglitazone and that pioglitazone exerts this
effect via a PPARγ independent manner.
The epidemic of T2DM has created a large need for new
hypoglycaemic and hypolipemic therapies; the PPARs
agonists represent a potentially important new group of
drugs with a mechanism of action differing from and per-
haps complementary to existing therapies. The emergence
of the angiogenesis altered signalling paradigm in T2DM
promises to enhance our understanding of cardiovascular
complications of diabetes and the advances in the under-
standing of the biology of angiogenesis enabled the devel-
opment of new therapeutic strategies for promoting
angiogenesis. Since pioglitazone is a drug currently used
with excellent tolerance and limited toxicity, our data
might offer a novel and potentially low toxic approach for
the treatment of diabetes-associated altered angiogenesis.
Our findings provide new information to understand the
biological effects of pioglitazone and its role in ischemia-
induced angiogenesis, with potentially important impli-
cations for the management of subjects affected by T2DM
cardiovascular complications.
Conclusion
The novel finding of the present study is that vascular Akt
system plays an essential role in restoring angiogenesis in
a. Representative photomicrographs of ischemic muscle sec- tions from pioglitazone+GW9662-treated and from pioglita- zone+FP-124-treated diabetic mice stained with antibody  directed against VEGF, 7 days after surgery. Positive staining  appears in brown Figure 3
a. Representative photomicrographs of ischemic 
muscle sections from pioglitazone+GW9662-treated 
and from pioglitazone+FP-124-treated diabetic mice 
stained with antibody directed against VEGF, 7 days 
after surgery. Positive staining appears in brown. Magnifica-
tion ×40. b. VEGF, Akt and pAkt expression 7 days after sur-
gery. Representative Western blot and optical density 
evaluation of VEGF Akt, pAkt and actin protein content in 
the ischemic legs of control, pioglitazone-treated, pioglita-
zone+GW9662-treated, STZ-diabetic, pioglitazone+FP-124-
treated and GW9662-treated mice. Pioglitazone normalized 
VEGF expression with enhanced phosphorylation of Akt in 
ischemic muscle. After pioglitazone administration, even 
when PPARγ activity was inhibited by GW9662, STZ-diabetic 
mice showed a normalized expression of VEGF and 
enhanced levels of p-Akt Ser473 in ischemic limbs compared 
to those treated with pioglitazone+FP-124 or with GW1929. 
Selective PPARγ agonist GW1929 or pioglitazone associated 
with selective Akt inhibitor FP-124 did not normalize VEGF 
expression in diabetic micevs STZ-diabetic, pioglitazone+FP-
124-treated and GW1929-treated mice. p < 0.05.Cardiovascular Diabetology 2009, 8:49 http://www.cardiab.com/content/8/1/49
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diabetic mice treated with pioglitazone. In fact, pioglita-
zone failed to promote blood flow recovery when Akt
activity was abolished, indicating that Akt is essential for
pioglitazone to promote collateral growth in response to
tissue ischemia. Finally, this is the first demonstration that
the positive effect of pioglitazone occurs via a PPARγ inde-
pendent mechanism. This study represents a step forward
towards a better understanding of mechanisms implicated
in the vascular effects of pioglitazone.
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